These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 12648581)

  • 21. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma.
    Dergham ST; Dugan MC; Kucway R; Du W; Kamarauskiene DS; Vaitkevicius VK; Crissman JD; Sarkar FH
    Int J Pancreatol; 1997 Apr; 21(2):127-43. PubMed ID: 9209954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical features and drug resistance characteristics of ovarian clear cell adenocarcinoma and analysis of its prognostic factors].
    Zhang CY; Guo HY; Li H; Wen HW; Liang XD; Qiao J
    Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):688-91. PubMed ID: 23159083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Co-mutation of p53, K-ras genes and accumulation of p53 protein and its correlation to clinicopathological features in rectal cancer.
    Pan ZZ; Wan DS; Chen G; Li LR; Lu ZH; Huang BJ
    World J Gastroenterol; 2004 Dec; 10(24):3688-90. PubMed ID: 15534934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is it possible to diagnose malignancy from fluid in cystic ovarian tumors?
    Yamada R; Maeda N; Oguri H; Adachi Y; Takeuchi T; Furihata M; Fukaya T
    Eur J Obstet Gynecol Reprod Biol; 2013 Nov; 171(1):96-100. PubMed ID: 24017961
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ARID1A mutations in endometriosis-associated ovarian carcinomas.
    Wiegand KC; Shah SP; Al-Agha OM; Zhao Y; Tse K; Zeng T; Senz J; McConechy MK; Anglesio MS; Kalloger SE; Yang W; Heravi-Moussavi A; Giuliany R; Chow C; Fee J; Zayed A; Prentice L; Melnyk N; Turashvili G; Delaney AD; Madore J; Yip S; McPherson AW; Ha G; Bell L; Fereday S; Tam A; Galletta L; Tonin PN; Provencher D; Miller D; Jones SJ; Moore RA; Morin GB; Oloumi A; Boyd N; Aparicio SA; Shih IeM; Mes-Masson AM; Bowtell DD; Hirst M; Gilks B; Marra MA; Huntsman DG
    N Engl J Med; 2010 Oct; 363(16):1532-43. PubMed ID: 20942669
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer.
    Tortola S; Marcuello E; González I; Reyes G; Arribas R; Aiza G; Sancho FJ; Peinado MA; Capella G
    J Clin Oncol; 1999 May; 17(5):1375-81. PubMed ID: 10334521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection.
    Isobe T; Hiyama K; Yoshida Y; Fujiwara Y; Yamakido M
    Jpn J Cancer Res; 1994 Dec; 85(12):1240-6. PubMed ID: 7852188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disappearance of steroid hormone dependency during malignant transformation of ovarian clear cell cancer.
    Akahane T; Sekizawa A; Okuda T; Kushima M; Saito H; Okai T
    Int J Gynecol Pathol; 2005 Oct; 24(4):369-76. PubMed ID: 16175084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Malignant transformation of endometriosis and genetic alterations of K-ras and microsatellite instability.
    Amemiya S; Sekizawa A; Otsuka J; Tachikawa T; Saito H; Okai T
    Int J Gynaecol Obstet; 2004 Sep; 86(3):371-6. PubMed ID: 15325855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma.
    Abe A; Minaguchi T; Ochi H; Onuki M; Okada S; Matsumoto K; Satoh T; Oki A; Yoshikawa H
    Hum Pathol; 2013 Feb; 44(2):199-207. PubMed ID: 22955107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
    Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
    Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
    Skírnisdóttir I; Seidal T
    Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PTEN promoter methylation and LOH of 10q22-23 locus in PTEN expression of ovarian clear cell adenocarcinomas.
    Ho CM; Lin MC; Huang SH; Huang CJ; Lai HC; Chien TY; Chang SF
    Gynecol Oncol; 2009 Feb; 112(2):307-13. PubMed ID: 19007975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of p53 and K-ras-2 topographic genotyping in endometrial carcinoma: a clinicopathologic and molecular comparison.
    Jones MW; Kounelis S; Hsu C; Papadaki H; Bakker A; Swalsky PA; Finkelstein SD
    Int J Gynecol Pathol; 1997 Oct; 16(4):354-60. PubMed ID: 9421075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer.
    Salmena L; Shaw P; Fans I; McLaughlin ; Rosen B; Risch H; Mitchell C; Sun P; Narod SA; Kotsopoulos J
    Eur J Gynaecol Oncol; 2015; 36(3):260-7. PubMed ID: 26189250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Promoter methylation of sFRP5 in patients with ovarian clear cell adenocarcinoma.
    Ho CM; Lai HC; Huang SH; Chien TY; Lin MC; Chang SF
    Eur J Clin Invest; 2010 Apr; 40(4):310-8. PubMed ID: 20486992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted next-generation sequencing for molecular diagnosis of endometriosis-associated ovarian cancer.
    Er TK; Su YF; Wu CC; Chen CC; Wang J; Hsieh TH; Herreros-Villanueva M; Chen WT; Chen YT; Liu TC; Chen HS; Tsai EM
    J Mol Med (Berl); 2016 Jul; 94(7):835-47. PubMed ID: 26920370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pathogenic role of PTEN tumor suppressor gene in ovarian cancer associated to endometriosis].
    Castiblanco G A; Pires N Y; Wistuba O I; Riquelme S E; Andrade M L; Corvalán R A
    Rev Med Chil; 2006 Mar; 134(3):271-8. PubMed ID: 16676097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression and mutation of p53 in tumor effusion cells of patients with ovarian carcinoma: response to cisplatin-based chemotherapy.
    Bar JK; Harłozińska A; Popiela A; Noga L
    Tumour Biol; 2001; 22(2):83-91. PubMed ID: 11125280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.